Lv5
970 积分 2022-02-24 加入
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
3天前
已完结
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
15天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
27天前
已完结
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
2个月前
已完结
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
2个月前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
2个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
